Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Dr. Marc Schegerin, COO and CFO, will take part in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference on Wednesday, May 15th, at 9:00 AM ET.

A live webcast of the panel discussion and fireside chat at the RBC Global Healthcare Conference will be available on the Investor section of Morphic’s website at www.morphictx.com. An archived replay will be available on the company’s website following the conference.

About Morphic TherapeuticMorphic Therapeutic is a biopharmaceutical company developing a portfolio of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis, and cancer. Morphic is also advancing its pipeline and discovery activities in collaboration with Schrödinger using its proprietary MInT technology platform which leverages the Company’s unique understanding of integrin structure and biology. For more information, visit www.morphictx.com.

ContactsMorphic TherapeuticChris Erdmanchris.erdman@morphictx.com617.686.1718

Morphic (NASDAQ:MORF)
過去 株価チャート
から 5 2024 まで 6 2024 Morphicのチャートをもっと見るにはこちらをクリック
Morphic (NASDAQ:MORF)
過去 株価チャート
から 6 2023 まで 6 2024 Morphicのチャートをもっと見るにはこちらをクリック